Lantern Pharma (NASDAQ: LTRN), an AI-driven precision oncology company, has announced the launch of ZetaOmics, the computational biology module of its multi-agentic AI co-scientist platform, withZeta.ai. The platform introduces an autonomous "Computational Biologist" agent designed to perform end-to-end bioinformatics and multi-omic analysis across cancer types, according to a press release.
Initially available through an early-access program for select academic, industry, and company collaborators, ZetaOmics is designed to automate complex research workflows while embedding domain-specific intelligence to improve analytical rigor and reproducibility. The platform combines 14 specialized tools that can autonomously design, execute, and validate biological analyses, detect potential flaws in experimental design, and generate publication-quality results with a complete audit trail.
Lantern said the platform expands withZeta.ai's commercial opportunity beyond rare cancers by targeting academic medical centers, biotechnology and pharmaceutical companies, cancer centers, and contract research organizations through subscription-based offerings and strategic collaborations. This move represents a new revenue stream for the company, as withZeta.ai is now commercially available as a subscription-based research platform for the global biomedical and drug development community.
The launch of ZetaOmics underscores the growing role of artificial intelligence in oncology research. By automating complex bioinformatics tasks, the platform could significantly reduce the time and cost associated with cancer research, potentially accelerating the discovery of new therapies. The ability to detect flaws in experimental design and maintain a full audit trail enhances reproducibility, a critical issue in biomedical research.
Lantern Pharma's clinical pipeline includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound in hematologic and solid tumors), and LP-300 (cisplatin/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern's wholly owned CNS-focused subsidiary.
The company operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas. For more details on the launch, the full press release is available at https://ibn.fm/9sIIl.
